-
1
-
-
70349240414
-
Chronic hepatitis B: update 2009
-
Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
-
(2009)
Hepatology
, vol.50
, pp. 661-662
-
-
Lok, A.S.1
McMahon, B.J.2
-
2
-
-
84862664371
-
EASL clinical practice guidelines: management of chronic hepatitis B virus infection
-
EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185.
-
(2012)
JHepatol
, vol.57
, pp. 167-185
-
-
-
3
-
-
84865376141
-
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
-
Liaw Y.F., Kao J.H., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
-
(2012)
Hepatol Int
, vol.6
, pp. 531-561
-
-
Liaw, Y.F.1
Kao, J.H.2
Piratvisuth, T.3
-
4
-
-
34247268523
-
Navigating the maze of hepatitis B treatments
-
Lok A.S. Navigating the maze of hepatitis B treatments. Gastroenterology 2007, 132:1586-1594.
-
(2007)
Gastroenterology
, vol.132
, pp. 1586-1594
-
-
Lok, A.S.1
-
5
-
-
29944436855
-
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
-
Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
-
(2006)
JAMA
, vol.295
, pp. 65-73
-
-
Chen, C.J.1
Yang, H.I.2
Su, J.3
-
6
-
-
33644858331
-
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
-
Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
-
(2006)
Gastroenterology
, vol.130
, pp. 678-686
-
-
Iloeje, U.H.1
Yang, H.I.2
Su, J.3
-
7
-
-
70449715760
-
Current management of hepatitis B virus infection before and after liver transplantation
-
Papatheodoridis G.V., Cholongitas E., Archimandritis A.J., et al. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009, 29:1294-1305.
-
(2009)
Liver Int
, vol.29
, pp. 1294-1305
-
-
Papatheodoridis, G.V.1
Cholongitas, E.2
Archimandritis, A.J.3
-
8
-
-
19544391413
-
Lamivudine for patients with chronic hepatitis B and advanced liver disease
-
Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEngl J Med 2004, 351:1521-1531.
-
(2004)
NEngl J Med
, vol.351
, pp. 1521-1531
-
-
Liaw, Y.F.1
Sung, J.J.2
Chow, W.C.3
-
9
-
-
84873726484
-
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
-
Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
-
(2013)
Lancet
, vol.381
, pp. 468-475
-
-
Marcellin, P.1
Gane, E.2
Buti, M.3
-
10
-
-
59149096271
-
Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study
-
Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. JViral Hepat 2009, 16:94-103.
-
(2009)
JViral Hepat
, vol.16
, pp. 94-103
-
-
Xu, W.M.1
Cui, Y.T.2
Wang, L.3
-
11
-
-
81355161368
-
Aprospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection
-
Han G.R., Cao M.K., Zhao W., et al. Aprospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. JHepatol 2011, 55:1215-1221.
-
(2011)
JHepatol
, vol.55
, pp. 1215-1221
-
-
Han, G.R.1
Cao, M.K.2
Zhao, W.3
-
12
-
-
42249113025
-
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
-
Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
-
(2008)
Ann Intern Med
, vol.148
, pp. 519-528
-
-
Loomba, R.1
Rowley, A.2
Wesley, R.3
-
13
-
-
79952231921
-
Management of hepatocellular carcinoma: an update
-
Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
-
(2011)
Hepatology
, vol.53
, pp. 1020-1022
-
-
Bruix, J.1
Sherman, M.2
-
14
-
-
84858658381
-
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma
-
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. JHepatol 2012, 56:908-943.
-
(2012)
JHepatol
, vol.56
, pp. 908-943
-
-
-
15
-
-
84984586846
-
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
-
Omata M., Lesmana L.A., Tateishi R., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010, 4:439-474.
-
(2010)
Hepatol Int
, vol.4
, pp. 439-474
-
-
Omata, M.1
Lesmana, L.A.2
Tateishi, R.3
-
16
-
-
84860304268
-
Effectiveness of hepatitis B treatment in clinical practice
-
e1361
-
Scaglione S.J., Lok A.S. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012, 142:1360-1368. e1361.
-
(2012)
Gastroenterology
, vol.142
, pp. 1360-1368
-
-
Scaglione, S.J.1
Lok, A.S.2
-
17
-
-
21244447705
-
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
-
Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. NEngl J Med 2005, 352:2682-2695.
-
(2005)
NEngl J Med
, vol.352
, pp. 2682-2695
-
-
Lau, G.K.1
Piratvisuth, T.2
Luo, K.X.3
-
18
-
-
4544239807
-
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
-
Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEngl J Med 2004, 351:1206-1217.
-
(2004)
NEngl J Med
, vol.351
, pp. 1206-1217
-
-
Marcellin, P.1
Lau, G.K.2
Bonino, F.3
-
19
-
-
48549107919
-
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
-
Buster E.H., Flink H.J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135:459-467.
-
(2008)
Gastroenterology
, vol.135
, pp. 459-467
-
-
Buster, E.H.1
Flink, H.J.2
Cakaloglu, Y.3
-
20
-
-
66449121130
-
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
-
e2161-2164
-
Marcellin P., Bonino F., Lau G.K., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136:2169-2179. e2161-2164.
-
(2009)
Gastroenterology
, vol.136
, pp. 2169-2179
-
-
Marcellin, P.1
Bonino, F.2
Lau, G.K.3
-
21
-
-
70649104668
-
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
-
Buster E.H., Hansen B.E., Lau G.K., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002-2009.
-
(2009)
Gastroenterology
, vol.137
, pp. 2002-2009
-
-
Buster, E.H.1
Hansen, B.E.2
Lau, G.K.3
-
22
-
-
65449117946
-
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
-
Brunetto M.R., Moriconi F., Bonino F., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
-
(2009)
Hepatology
, vol.49
, pp. 1141-1150
-
-
Brunetto, M.R.1
Moriconi, F.2
Bonino, F.3
-
23
-
-
65449123444
-
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
-
Moucari R., Mackiewicz V., Lada O., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
-
(2009)
Hepatology
, vol.49
, pp. 1151-1157
-
-
Moucari, R.1
Mackiewicz, V.2
Lada, O.3
-
24
-
-
84874471701
-
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B
-
Lampertico P., Vigano M., Cheroni C., et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896.
-
(2013)
Hepatology
, vol.57
, pp. 890-896
-
-
Lampertico, P.1
Vigano, M.2
Cheroni, C.3
-
25
-
-
75449107726
-
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
-
Chang T.T., Lai C.L., Kew Yoon S., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
-
(2010)
Hepatology
, vol.51
, pp. 422-430
-
-
Chang, T.T.1
Lai, C.L.2
Kew Yoon, S.3
-
26
-
-
66149115173
-
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
-
Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
-
(2009)
Hepatology
, vol.49
, pp. 1503-1514
-
-
Tenney, D.J.1
Rose, R.E.2
Baldick, C.J.3
-
27
-
-
33744531146
-
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
-
Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-2049.
-
(2006)
Gastroenterology
, vol.130
, pp. 2039-2049
-
-
Sherman, M.1
Yurdaydin, C.2
Sollano, J.3
-
28
-
-
33644818518
-
Acomparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
-
Chang T.T., Gish R.G., de Man R., et al. Acomparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. NEngl J Med 2006, 354:1001-1010.
-
(2006)
NEngl J Med
, vol.354
, pp. 1001-1010
-
-
Chang, T.T.1
Gish, R.G.2
de Man, R.3
-
29
-
-
18444367980
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
-
Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186-194.
-
(2002)
Hepatology
, vol.36
, pp. 186-194
-
-
Perrillo, R.P.1
Lai, C.L.2
Liaw, Y.F.3
-
30
-
-
84865490229
-
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B
-
e611
-
Lok A.S., Trinh H., Carosi G., et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012, 143:619-628. e611.
-
(2012)
Gastroenterology
, vol.143
, pp. 619-628
-
-
Lok, A.S.1
Trinh, H.2
Carosi, G.3
-
31
-
-
58649096155
-
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B
-
Liaw Y.F., Gane E., Leung N., et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
-
(2009)
Gastroenterology
, vol.136
, pp. 486-495
-
-
Liaw, Y.F.1
Gane, E.2
Leung, N.3
-
32
-
-
73149085984
-
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function
-
Lange C.M., Bojunga J., Hofmann W.P., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001-2006.
-
(2009)
Hepatology
, vol.50
, pp. 2001-2006
-
-
Lange, C.M.1
Bojunga, J.2
Hofmann, W.P.3
-
33
-
-
51349107091
-
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
-
Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
-
(2008)
Hepatology
, vol.48
, pp. 750-758
-
-
Marcellin, P.1
Chang, T.T.2
Lim, S.G.3
-
34
-
-
78751491184
-
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
-
Liaw Y.F., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
-
(2011)
Hepatology
, vol.53
, pp. 62-72
-
-
Liaw, Y.F.1
Sheen, I.S.2
Lee, C.M.3
-
35
-
-
79959551969
-
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study
-
Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011, 54:91-100.
-
(2011)
Hepatology
, vol.54
, pp. 91-100
-
-
Liaw, Y.F.1
Raptopoulou-Gigi, M.2
Cheinquer, H.3
-
36
-
-
75449093009
-
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B
-
Lee H.W., Lee H.J., Hwang J.S., et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010, 51:415-421.
-
(2010)
Hepatology
, vol.51
, pp. 415-421
-
-
Lee, H.W.1
Lee, H.J.2
Hwang, J.S.3
-
37
-
-
84865487986
-
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir
-
e621
-
Hadziyannis S.J., Sevastianos V., Rapti I., et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012, 143:629-636. e621.
-
(2012)
Gastroenterology
, vol.143
, pp. 629-636
-
-
Hadziyannis, S.J.1
Sevastianos, V.2
Rapti, I.3
-
38
-
-
84860320431
-
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients
-
Epub ahead of print
-
Piratvisuth T., Marcellin P., Popescu M., et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011, Epub ahead of print.
-
(2011)
Hepatol Int
-
-
Piratvisuth, T.1
Marcellin, P.2
Popescu, M.3
-
39
-
-
77957958049
-
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
-
Sonneveld M.J., Rijckborst V., Boucher C.A., et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52:1251-1257.
-
(2010)
Hepatology
, vol.52
, pp. 1251-1257
-
-
Sonneveld, M.J.1
Rijckborst, V.2
Boucher, C.A.3
-
40
-
-
79952227475
-
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
-
Snow-Lampart A., Chappell B., Curtis M., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
-
(2011)
Hepatology
, vol.53
, pp. 763-773
-
-
Snow-Lampart, A.1
Chappell, B.2
Curtis, M.3
|